Efficacy of salvage surgery for hepatocellular carcinoma following conversion therapy

Table 1 Demographic and baseline characteristics of patients, n (%)

Characteristics	Total cohort (n = 28)
Age (year), mean ± SD	57.18 ± 12.46
Age, years
< 65	19 (67.9)
≥ 65	9 (32.1)
Gender
Male	25 (89.3)
Female	3 (10.7)
Etiology
HBV	22 (78.6)
HCV	1 (3.6)
Non-viral	5 (17.9)
ECOG-PS
0	25 (89.3)
1	3 (10.7)
Child-Pugh class
A	23 (82.1)
B	5 (17.9)
Pre-treatment AFP (ng/mL)
< 400	7 (25.0)
≥ 400	21 (75.0)
BCLC staging system
A	1 (3.6)
B	10 (35.7)
C	17 (60.7)
Vascular invasion
Present	17 (60.7)
Absent	11 (39.3)
Maximum tumor diameter (cm), mean ± SD	7.38 ± 3.67
Number of tumors
1	9 (32.1)
2	4 (14.3)
3	2 (7.1)
≥ 4	13 (46.4)
irAEs
Yes	6 (21.4)
No	22 (78.6)
Post-operative complications
Yes	4 (14.3)
No	24 (85.7)
Post-operative adjuvant therapy
Yes	16 (57.1)
No	12 (42.9)
ALT level (IU/L)
< 40	20 (71.4)
≥ 40	8 (28.6)
AST level (IU/L)
< 40	15 (53.6)
≥ 40	13 (46.4)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; ECOG-PS: Eastern Cooperative Oncology Group performance status; Child-Pugh: Child-Pugh score; AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; irAEsA: Immune-related adverse events; ALT: Alanine transaminase; AST: Aspartate transaminase.